Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma

Anti-Cancer Drugs

Volumn 18, Issue 10, 2007, Pages 1133-1137

  Yang, Huayu ^a   Guo, Wei ^a   Xu, Bo ^a   Li, Min ^a   Cui, Jingrong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Antiproliferation; Apoptosis; Cell cycle; Implanted mice hepatoma; Norcantharidin Nd3II

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; MIANSERIN; NORCANTHARIDIN; NORCANTHARIDIN GD2; NORCANTHARIDIN LA; NORCANTHARIDIN ND3L; NORCANTHARIDIN ND3LL; P21 ACTIVATED KINASE; PROTEIN BAX; PROTEIN BCL 2; RHODAMINE; SULFARHODAMINE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CDC2 PROTEIN KINASE; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED ICR; NEODYMIUM; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34748853131     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282eeb1c5     Document Type: Article

References (26)

1. Suzui M, Masuda M, Lim J, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21CIP1 and inhibition of expression of cyclin D11. Cancer Res 2002; 62:3997-4006.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 53:1253-1257.
3. Carrel JE, Eisner T, Lo TC, Wiley AL Jr, Ansfield FJ, Brandenburg JH, et al. Cantharidin: potent feeding deterrent to insects. Science 1974; 183:755-757.
4. Graziano MJ, Waterhouse AL, Casida JE. Cantharidin poisoning associated with specific binding site in liver. Biochem Biophys Res Commun 1987; 149:79-85.
5. Graziano MJ, Pessah IN, Matsuzawa M, Casida JE. Partial characterization of specific cantharidin binding sites in mouse tissues. Mol Pharmacol 1988; 33:706-712.
6. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989; 26:147-162.
7. 2/M apoptosis is dependent on wild-type p53 gene. Biochem Biophys Res Commun 2000; 276:278-285.
8. McCluskey A, Bowyer MC, Collins E, Sim ATR, Sakoff JA, Baldwin ML, et al. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg Med Chem Lett 2000; 10:1687-1690.
9. Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997; 117:93-98.
10. Liu XH, Blazsek I, Comisso M, Legras S, Marion S, Quittet P, et al. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 1995; 31A:953-963.
11. Wu De-zhu, Cui Jing-rong. China patent. Application No 200510069072.2.
12. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
13. Kumara SS, Hauat BT. Extraction, isolation and characterization of antitumor principle, a-hederin, from the seeds of Nigella sativa. Planta Med 2001; 67:29-32.
14. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Method 1991; 139:271-279.
15. Zoe AS, Matthew DW, Jennifer AP. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003; 24:139-145.
16. Will R. Cancer and the role of cell cycle check points. Rev Undergrad Res 2002; 1:1-7.
17. Charles JS. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-3695.
18. 2/M transition. Biochem Biophys Acta 2001; 1519:1-12.
19. 2-phase DNA damage checkpoint. Trends Cell Biol 2000; 20:296-303.
20. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281:1322-1326.
21. Coleman ML, Marshall CJ, Olson MF. Ras promotes p21Waf1/Cip1 protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 2003; 22:2036-2046.
22. Garcia-Wilson E, Perkins ND. p21WAF1/CIP1 regulates the p300 HSumoylation motif CRD1 through a C-terminal domain independently of cyclin/CDK binding. Cell Cycle 2005; 4:1113-1119.
23. Wei H, John JK. Anticancer therapy targeting the apoptotic pathway. Oncology 2003; 4:721-729.
24. Andrew M. Cyclin ubiquitination: the destructive end of mitosis. Cell 1995; 81:149-152.
25. Antonsson B, Matinou JC. The Bcl-2 protein family. Exp Cell Res 2000; 256:50-57.
26. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387:773-776.